22 lines
7.1 KiB
JSON
22 lines
7.1 KiB
JSON
{
|
|
"2026-03-24": {
|
|
"company_of_interest": "RTX",
|
|
"trade_date": "2026-03-24",
|
|
"market_report": "RTX Technical Analysis (2026-03-24): Price $194.82 (near lower Bollinger Band $194.08), 50-SMA $200.39 (broken below, resistance), 10-EMA $201.62 (steep decline), 200-SMA $171.30 (intact, long-term uptrend). MACD -0.004 (bearish crossover confirmed), histogram -1.52 (8 consecutive expanding negative bars). RSI 40.11 (declining toward oversold). ATR $5.46 (+18% vs prior month). Down 6.4% in 10 sessions from $208.23. 52-week range $112.27-$214.50. Institutional buying at highs (12.5M shares Mar 2) now underwater. Key support: $194.08 (lower BB), $192.62 (period low), $171.30 (200-SMA). Near-term bias: BEARISH. Long-term bias: BULLISH.",
|
|
"sentiment_report": "RTX Sentiment (Mar 17-24, 2026): Overall MIXED-CAUTIOUSLY BULLISH (LT) / NEUTRAL-TO-BEARISH (ST). Key themes: (1) Rare earth supply chain risk - 2027 hard deadline to eliminate Chinese-origin materials from AMRAAM/Tomahawk; U.S. claimed ~2-month stockpile; HIGH impact. (2) Missile demand/U.S.-Iran conflict - IBD named RTX clear outperformer; $11.74B missile contract; hypersonic investment; HIGH impact. (3) Daily underperformance on up-market days (distribution signal); down 1.32%-1.69% on positive market days. (4) Patriot interceptor linked to Bahrain civilian blast Mar 9 (Reuters) - reputational/legal risk. (5) Valuation fatigue - 52% 1-year gain, 7.2% YTD. Anduril $20B Army deal signals defense-tech shift. WSJ: 'Why Defense-Contractor Stocks Aren't Rallying.' Nvidia/AMD rally on war fears easing = de-escalation signal.",
|
|
"news_report": "RTX News & Macro (2026-03-24): Active U.S.-Iran conflict driving Tomahawk/AMRAAM/Patriot consumption - Pentagon replenishment urgency. European rearmament providing secular demand tailwind - NATO budget increases = Patriot/AMRAAM/radar orders. $11.74B contract secured; hypersonic weapons development ongoing. Rare earth supply chain: 2027 hard deadline, Chinese-origin materials in AMRAAM/Tomahawk, ~2-month U.S. stockpile per Chinese publication. RTX underperforming on up-market days. Patriot interceptor linked to Bahrain civilian blast Mar 9 (Reuters). Anduril $20B Army software deal = structural shift toward defense-tech. WSJ: production bottlenecks limiting earnings leverage. Oil shock/inflation environment groups RTX with macro beneficiaries. De-escalation signals from tech sector. Overall: Moderately bullish with rare earth risk as primary tail risk.",
|
|
"fundamentals_report": "RTX Fundamentals (Q4 2025): Market cap $262.2B. Revenue TTM $88.6B (+19% YoY). PE TTM 39.2x, Forward PE 25.9x. EPS TTM $4.97, Forward EPS $7.51 (51% implied growth). Dividend yield 1.4%, Beta 0.41. Net debt $30.5B (down $5.2B from $35.7B in Q4 2024). FCF FY2025 ~$7.4B. Deferred revenue $21.6B (grew from $18.6B - backlog indicator). Q4 2025: Revenue $24.24B, Operating Income $2.60B, Net Income $1.62B. Q2 2025 FCF: -$194M (seasonal weakness). H2 2025 OCF exceptional: $4.64B (Q3) + $4.17B (Q4). Goodwill/intangibles $85.2B (50% of assets). Negative tangible book -$19.9B. Total debt $39.5B. Interest expense $370-514M/quarter. GTF engine powder metal inspections ongoing. Rising AR: $10.98B to $14.70B. Working capital improved to $1.55B. ROE 10.95%. Overall: Constructive/positive with improving cash generation and declining debt.",
|
|
"investment_debate_state": {
|
|
"bull_argument": "RTX at $194.82 is a discounted entry point. Revenue +19% YoY to $88.6B TTM. Forward EPS $7.51 vs TTM $4.97 = 51% growth, Forward PE 25.9x. FCF $7.4B with $5.2B net debt reduction. Deferred revenue backlog $21.6B. Active U.S.-Iran conflict drives Tomahawk/AMRAAM/Patriot replenishment urgency. NATO rearmament = secular multi-year demand. RTX is monopoly supplier in Patriot/AMRAAM/Tomahawk. $11.74B contract secured. 200-SMA $171.30 confirms long-term uptrend intact. RSI 40.11 approaching oversold = patient buyer zone. Lower BB $194.08 = mean reversion entry. Rare earth and GTF are known/manageable with $7.4B FCF. Beta 0.41 = defensive macro anchor.",
|
|
"bear_argument": "Confirmed technical breakdown: down 6.4% in 10 sessions, below 50-SMA, MACD bearish crossover with 8 consecutive expanding negative histogram bars (-1.52), RSI 40.11 declining, ATR +18%. Real downside to 200-SMA $171.30. Valuation stretched: 39.2x TTM PE. Balance sheet fragile: $39.5B debt, $30.5B net debt, $85.2B goodwill (50% of assets), negative tangible book -$19.9B. Q2 2025 FCF -$194M. Rare earth: 2-month stockpile, 2027 hard deadline, AMRAAM/Tomahawk depend on Chinese-origin materials. GTF engine: multi-year open-ended liability. Anduril $20B Army deal = structural DOD shift. Cost-plus caps margin upside. Production bottlenecks limit earnings leverage."
|
|
},
|
|
"trader_investment_decision": "HOLD. Current price $194.82 is above the plan's own Tranche 1 entry range ($185-$187). No compelling technical reversal signal. Long-term thesis intact but timing does not yet call for capital deployment. Wait for $185-$187 (Tranche 1) or $172-$175 (Tranche 2). Stop at $158. FINAL TRANSACTION PROPOSAL: HOLD",
|
|
"risk_debate_state": {
|
|
"aggressive_argument": "HOLD is leaving money on the table. Stock near lower Bollinger Band $194.08, RSI approaching oversold, 51% forward EPS growth, $21.6B backlog, active NATO/Iran demand accelerating. From $194, risk-reward to $220 still adequate. Partial entry now with add on weakness is better than cash on sidelines. Rare earth and GTF are known/priced.",
|
|
"conservative_argument": "HOLD is correct discipline. Risk-reward from $194.82 is 0.68:1 (below 2:1 minimum). 8 consecutive negative MACD bars = no floor, band-walking risk. Rare earth 2027 with 2-month stockpile is NOT priced. GTF multi-year open-ended. Goodwill $85.2B / negative tangible book = structural fragility. Q2 FCF -$194M. Wait for $172-$175.",
|
|
"neutral_argument": "Risk-reward from $194 is 1.35:1 - below 2:1 minimum. Rare earth 2027 is binary risk deserving reduced Tranche 1 sizing (~40% of position). Staged entry: Tranche 1 at $185-$187 (40% size), Tranche 2 at $172-$175 (60%). Hold here with pre-defined triggers. Anduril deal signals structural long-term headwind."
|
|
},
|
|
"investment_plan": "RECOMMENDATION: BUY (Staged Entry). Staged entry: Tranche 1 (30%) at $185-$187, Tranche 2 (40%) at $172-$175 near 200-SMA, Tranche 3 (30%) reserve below $170 or redeploy on 50-SMA reclaim. Hard stop at $158. 12-month target $220-$235. 24-month target $255-$270. Holding period 18-36 months. Monitor GTF liability and rare earth supply quarterly.",
|
|
"final_trade_decision": "HOLD. Deploy capital in stages on weakness: Tranche 1 at $185-$187 (40% of intended position, reduced for rare earth binary risk). Tranche 2 at $172-$175 near 200-SMA (remaining 60%). Hard stop at $158. 12-month target $220-$235. 18-month horizon. Risk-reward at current price (0.68:1) does not meet 2:1 threshold. Three structural risks require monitoring: goodwill/negative tangible book, GTF open-ended liability, rare earth 2027 binary deadline. Long-term thesis intact: RTX as monopoly-class defense platform with 51% forward EPS growth and $21.6B backlog."
|
|
}
|
|
} |